Somewhat Positive News Coverage Somewhat Unlikely to Impact Intec Pharma (NASDAQ:NTEC) Share Price

News stories about Intec Pharma (NASDAQ:NTEC) have been trending somewhat positive on Saturday, according to Accern Sentiment. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intec Pharma earned a news impact score of 0.21 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.0285586070155 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

• Intec Pharma (NTEC) Prices 10.6M Share Offering at $4.70/Sh (streetinsider.com)
• Intec Pharma : Midday Gainers / Losers (4-traders.com)
• Intec Pharma Ltd: Jumps on equity raise to fund Parkinson’s drug (timesofindia.indiatimes.com)
• Intec Pharma Announces Pricing of $50.0 Million Public Offering of Ordinary Shares (finance.yahoo.com)
• Intec Pharma (NTEC) Plans Public Offering of Ordinary Shares (streetinsider.com)

Intec Pharma (NASDAQ NTEC) opened at 6.15 on Friday. Intec Pharma has a 52 week low of $4.20 and a 52 week high of $6.37. The company’s 50-day moving average is $5.46 and its 200 day moving average is $5.26. The company’s market capitalization is $84.49 million.

A number of equities analysts recently issued reports on the stock. Zacks Investment Research cut shares of Intec Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday. Roth Capital set a $10.00 price target on shares of Intec Pharma and gave the company a “buy” rating in a research report on Thursday, August 10th. ValuEngine cut shares of Intec Pharma from a “hold” rating to a “sell” rating in a research report on Friday, June 9th. Finally, Maxim Group set a $9.00 price objective on shares of Intec Pharma and gave the company a “buy” rating in a research note on Wednesday, May 24th.

TRADEMARK VIOLATION WARNING: This piece was published by [[site]] and is the sole property of of [[site]]. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at [[permalink]].

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.